Stockscreener 앱 받기
226.08
1.15%
-2.63
시간 외 거래:
226.44
0.36
+0.16%
Abbvie Inc 주식(ABBV)의 최신 뉴스
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer - PR Newswire
Is AbbVie Inc. (4AB) stock undervalued after correctionWeekly Trade Summary & Community Consensus Picks - Newser
How Strong Is AbbVie's Immunology Franchise After Humira's LOE? - The Globe and Mail
Could buying AbbVie today set you up for life? - MSN
Could Buying AbbVie Today Set You Up for Life? - Nasdaq
Dry Eye Disease Treatment Market Outlook Report 2032 | Alcon - openPR.com
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 - The Motley Fool
Why AbbVie Inc. stock attracts global investorsMarket Performance Summary & Fast Exit and Entry Strategy Plans - Newser
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts - ts2.tech
Assessing AbbVie’s (ABBV) Valuation After New Cancer Data, EPKINLY Approval, and Dividend Hike - simplywall.st
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
AbbVie looks to expand use cases for migraine drug after promising study - Crain's Chicago Business
Invesco Ltd. Lowers Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie Inc. stock undervalued at current priceSwing Trade & Weekly High Conviction Ideas - Newser
AbbVie (ABBV) Stock on December 2, 2025: Dividend Hike, Cancer Pipeline Momentum and 2026 Outlook - ts2.tech
Metastatic Non-Small Cell Lung Cancer Market on Track for Major Expansion by 2034, According to DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73 - simplywall.st
AbbVie to feature new data at ASH 2025 - MarketScreener
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - Investing News Network
AbbVie (NYSE: ABBV) highlights ASH 2025 advances in T-cell engagers, BCL-2 and ADCs - Stock Titan
2 Top Dividend Stocks to Buy Now and Hold For a Decade - AOL.com
Portfolio Design Labs LLC Has $571,000 Stake in AbbVie Inc. $ABBV - MarketBeat
Shelton Capital Management Has $7.29 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Loomis Sayles & Co. L P Purchases 18,866 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Fisher Asset Management LLC - MarketBeat
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
Willis Johnson & Associates Inc. Decreases Holdings in AbbVie Inc. $ABBV - MarketBeat
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Sepio Capital LP Has $38.93 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating - Seeking Alpha
AbbVie Inc. $ABBV is Distillate Capital Partners LLC's 4th Largest Position - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Everstar Asset Management LLC - MarketBeat
Edgestream Partners L.P. Takes $12.43 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress - PR Newswire
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets - ts2.tech
AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.73 - Yahoo Finance
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength - ts2.tech
Aug Final Week: How cyclical is AbbVie Inc. stock compared to rivalsDip Buying & Capital Efficiency Focused Strategies - moha.gov.vn
3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - Finviz
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate - ts2.tech
Total liabilities & shareholders' equities of AbbVie, Inc. – SIX:ABBV - TradingView
Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance? - Yahoo Finance
ABBVAbbvie Inc Stock Price and Quote - Finviz
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
AbbVie (ABBV) Gains Canadian Support for Ulcerative Colitis Trea - GuruFocus
AbbVie Announces Positive Reimbursement Recommendations for SKYRIZI® in Ulcerative Colitis by Canada's Drug Agency - Quiver Quantitative
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - MarketScreener
3 Dividend-Paying Stocks that Are Up Over 30% in 2025 - Tokenist
AbbVie Unit Fails To Revive Dermal Filler Patent On Appeal - Law360
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AbbVie (ABBV) Stock Price, Quote, News & History - Benzinga
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights - Nasdaq
Medicare negotiates discounts on two AbbVie drugs - Crain's Chicago Business
Is AbbVie Stock Outperforming the Nasdaq? - Yahoo Finance
CollPlant's Strategic Focus with AbbVie (ABBV) Gains Spotlight - GuruFocus
Pacific Wealth Management's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec - Investing News Network
BioMed X, AbbVie Launch New Research Project Focused on Anhedonia - Contract Pharma
AbbVie Inc (NYSE:ABBV) Shares Edge Lower Following Sector Review - Kalkine Media
IgG4-related disease Market Size was USD 170 million in 2024, estimates DelveInsight | Zenas BioPharma, Horizon Therapeutics, Sanofi, Roche, AbbVie, Gilead Sciences, Takeda - Barchart.com
How Recent Developments Are Shaping Analyst Views on AbbVie’s Future Edge - Yahoo Finance
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
Full FDA Approval of EPKINLY Combo Therapy Could Be a Game Changer for AbbVie (ABBV) - Yahoo Finance
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference - Investing News Network
0.27%
자본화:
|
볼륨(24시간):